EUCTR2018-004067-31-CZ
Active, not recruiting
Phase 1
Autologous bone marrow-derived mesenchymal stem cells seeded on a 3D scaffold in treatment of knee cartilage defects. Prospective open-label study to assess safety and feasibility.
Overview
- Phase
- Phase 1
- Intervention
- Not specified
- Conditions
- Not specified
- Sponsor
- Bioinova, s.r.o.
- Enrollment
- 6
- Status
- Active, not recruiting
- Last Updated
- 4 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •1\.Adult patients of either sex, age between 18 and 60 years.
- •2\.Confirmed diagnosis of chondral defects of the weight bearing compartment of the knee joint up to the radiologically confirmed knee osteoarthrosis stage III, the cause of the defect being either trauma or progressive degeneration.
- •3\.Scheduled to undergo an open surgery of the knee for the chondral defect management (namely microfracture followed by the application of the 3D scaffold chondrotissue®).
- •4\.No previous knee surgery due to a chondral defect.
- •5\.Preoperative level of haemoglobin at least 110 g per L.
- •6\.Preoperative level of platelet count higher than 150 000 per mL.
- •7\.Able to provide written informed consent.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1\.2 Adults (18\-64 years) yes
Exclusion Criteria
- •1\.Ligament laxity or axial deformities over 10° on the study knee.
- •2\.Systemic corticosteroid or immunosuppressive medication, or anticoagulant therapy, ongoing or recent, (used regularly during the last 3 months before the screening visit). Intraarticular corticosteroid medication is not allowed within the same time period.
- •3\.Active infection or any other condition limiting the healing (e.g., immunodeficiency, hepatitis, active tuberculosis, neoplasm, metabolic disorders, drug abuse, etc.).
- •4\.Concurrent or previous cancer.
- •5\.Blood, plasma or platelet transfusion during previous 8 weeks.
- •6\.Pregnant or lactating women.
- •7\.Subject not using two reliable methods method of birth control.
- •8\.BMI higher than 40\.
- •9\.Clinical instability of the joint objectified during the surgery.
Outcomes
Primary Outcomes
Not specified
Similar Trials
Completed
Not Applicable
Allogeneic Bone Marrow Derived Mesenchymal Stem Cells for the Treatment of Fistulas in Patients with Refractory Perianal Crohn*s DiseasefistulaM. Crohn10017969NL-OMON36386eids Universitair Medisch Centrum21
Active, not recruiting
Not Applicable
Allogeneic Bone Marrow Derived Mesenchymal Stem Cellsfor the Treatment of Fistulas in Patients withRefractory Perianal Crohn’s Disease - allo bmMSCs CD fistulaEUCTR2009-015680-14-NLeiden University Medical Center
Recruiting
Phase 1
Safety and efficacy of autologous stem cells derived from bone marrow in treating OsteoarthritisCTRI/2010/091/001044International Stemcell Services Limited117, Venkateshwara Nagar, Jakkur, Bengaluru 56006410
Recruiting
Phase 2
Allogeneic bone marrow derived mesenchymal stromal cells for the treatment of refractory proctitis in Ulcerative ColitisUlcerative Colitis10017969NL-OMON48876eids Universitair Medisch Centrum14
Active, not recruiting
Phase 1
Mesenchymal Stromal Cells for the treatment of Ulcerative Colitislcerative ColitisMedDRA version: 20.1Level: LLTClassification code 10045365Term: Ulcerative colitisSystem Organ Class: 100000004856Therapeutic area: Diseases [C] - Immune System Diseases [C20]EUCTR2017-003524-75-NLeiden University Medical Center14